Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EU to fund transfer of COVID-19 patients across borders to prevent hospitals collapse

10/29/2020 | 04:49pm EST

BRUSSELS, Oct 29 (Reuters) - The European Union will finance the transfer of patients across borders within the bloc to prevent hospitals from getting overwhelmed as COVID-19 infections and hospitalizations spike in the continent.

After a video conference of EU leaders to discuss the health crisis on Thursday, the head of the EU Commission Ursula von der Leyen said the EU executive had made available 220 million euros ($260 million) to move COVID-19 patients across borders.

"The spread of the virus will overwhelm our healthcare systems if we do not act urgently," she said.

At the meeting leaders agreed to better coordinate efforts to battle the virus as infections in Europe exceeded 10 million, making the continent again the epicenter of the pandemic.

EU countries want to avoid divisions which dogged the 27-nation bloc at the beginning of the pandemic, when nations vied with each other to buy scarce medical equipment.

To better trace infections, von der Leyen said the EU would work for the quick validation at EU level of rapid antigen tests, which allow quicker results than the standard PCR (polymerase chain reaction) molecular kits.

The Commission is also intensifying its efforts to get potential vaccines against the new coronavirus.

The EU was in talks with four companies, and had already sealed supply deals with another three, she said.

The EU has secured potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson .

It has also said it is in talks with Moderna, CureVac and a partnership of Pfizer and BionTech. Reuters reported in September that the EU was also in preliminary talks with Novavax.

The chair of the meeting, Charles Michel, said EU leaders committed to a fair distribution of vaccines once available. That would be done in proportion to population, von der Leyen said.

Michel said vaccination plans at a national level were crucial to make sure the first limited doses of vaccines could be distributed quickly to those most in need.

Many countries however have not yet defined their inoculation plans, and have different targets.

($1 = 0.8461 euros) (Reporting by Francesco Guarascio, Robin Emmott, Jan Strupczewski; editing by Richard Pullin)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.05% 7869 Delayed Quote.2.60%
MODERNA, INC. 20.24% 152.74 Delayed Quote.680.88%
NOVAVAX, INC. 10.99% 139.5 Delayed Quote.3,058.04%
PFIZER, INC. 2.90% 38.31 Delayed Quote.3.21%
SANOFI -0.59% 84.71 Real-time Quote.-5.48%
All news about ASTRAZENECA PLC
08:14aAstellas Receives Approval of EVRENZO in Japan for the Treatment of Anemia of..
07:07aQ&A : Where are we in the COVID-19 vaccine race?
07:00aModerna to seek US, EU emergency authorization Monday after COVID-19 vaccine ..
06:53aASTRAZENECA : UBS drops its Sell rating
05:29aASTRAZENECA : Forxiga approved in Japan for chronic heart failure
02:11aASTRAZENECA : Forxiga approved in Japan for chronic heart failure
11/29ASTRAZENECA : Lokelma label update approved in China for patients with hyperkala..
11/29UK stocks up on vaccines, hopes to start virus shots in days
11/29ASTRAZENECA : India regulators probe alleged AstraZeneca shot reaction, trial co..
11/29UK secures two million more doses of Moderna's COVID-19 vaccine
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,8x
Yield 2020 2,70%
Capitalization 137 B 137 B -
EV / Sales 2020 5,65x
EV / Sales 2021 4,92x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,84 $
Last Close Price 104,09 $
Spread / Highest target 49,4%
Spread / Average Target 17,1%
Spread / Lowest Target -36,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.82%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER, INC.3.21%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049